Literature DB >> 15744452

Correlation between patient recall of bone densitometry results and subsequent treatment adherence.

Cynthia S Pickney1, Jon A Arnason.   

Abstract

Treatment of osteoporosis is often inadequate. One reason can be insufficient patient education following diagnostic bone densitometry (DXA). Therefore, we studied how patients are informed and treated following their first DXA. Individuals who had DXA at a rural hospital in Wisconsin were surveyed with a questionnaire regarding their post-test education and prescribed treatment. Their DXA results and the specialty of their clinician were also recorded. Eighty percent of the 1,014 participants were informed of their results. Of the 341 participants who had normal bone mineral density (BMD), 63% reported correct results, while only 31% of the 309 who had osteopenia and 50% of the 364 who had osteoporosis reported correct results. Accuracy in reporting was not affected by the patients' age or the specialty of their clinicians. Following DXA, 339 patients (33%) were started on medications; 86% of those remained on some prescribed therapy for osteoporosis, but 140 (41%) did not continue the initial medication. Reasons for discontinuation included side effects (48%) and cost (26%). Patients with low BMD who correctly reported their results were more likely to have received a medication and to continue to take it ( p <0.0001). Calcium supplements were recommended to 65% of those not taking calcium prior to DXA. Internists were more likely than family practitioners to recommend calcium, and their patients reported better medication adherence, as did those with osteoporosis compared with osteopenia. We conclude that, while most participants are informed of the results of their DXAs, the retained information may not be accurate. Correct understanding of DXA results may lead to higher treatment rates and better adherence to treatment among patients with low BMD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15744452     DOI: 10.1007/s00198-004-1818-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  21 in total

1.  Epidemiology of osteoporosis.

Authors:  C Cooper
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

2.  Do patients receive appropriate information and treatment following bone mineral density measurements?

Authors:  R Kilding; R Eastell; N Peel
Journal:  Rheumatology (Oxford)       Date:  2002-09       Impact factor: 7.580

Review 3.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

4.  Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures.

Authors:  H Castel; D Y Bonneh; M Sherf; Y Liel
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

5.  Assessment of physician responses to abnormal results of bone densitometry studies.

Authors:  P A Economides; V G Kaklamani; I Karavas; G I Papaioannou; S Supran; R D Mirel
Journal:  Endocr Pract       Date:  2000 Sep-Oct       Impact factor: 3.443

6.  The burden of osteoporosis in California, 1998.

Authors:  W Max; P Sinnot; C Kao; H-Y Sung; D P Rice
Journal:  Osteoporos Int       Date:  2002       Impact factor: 4.507

7.  Early discontinuation of treatment for osteoporosis.

Authors:  Anna N A Tosteson; Margaret R Grove; Cristina S Hammond; Megan M Moncur; G Thomas Ray; Gwen M Hebert; Alice R Pressman; Bruce Ettinger
Journal:  Am J Med       Date:  2003-08-15       Impact factor: 4.965

Review 8.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

9.  Mortality following fractures in older women. The study of osteoporotic fractures.

Authors:  W S Browner; A R Pressman; M C Nevitt; S R Cummings
Journal:  Arch Intern Med       Date:  1996-07-22

10.  Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.

Authors:  Carmen Turbí; Gabriel Herrero-Beaumont; Juan Carlos Acebes; Antonio Torrijos; Jenaro Graña; Roberto Miguélez; JoséAntonio Sacristán; Fernando Marín
Journal:  Clin Ther       Date:  2004-02       Impact factor: 3.393

View more
  41 in total

1.  Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.

Authors:  S M Cadarette; D H Solomon; J N Katz; A R Patrick; M A Brookhart
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

2.  Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.

Authors:  J R Curtis; A O Westfall; J J Allison; A Freeman; K G Saag
Journal:  Osteoporos Int       Date:  2006-05-19       Impact factor: 4.507

Review 3.  Review of adherence to medications for the treatment of osteoporosis.

Authors:  Deborah T Gold; Stuart Silverman
Journal:  Curr Osteoporos Rep       Date:  2006-03       Impact factor: 5.096

4.  Absolute fracture risk reporting in clinical practice: a physician-centered survey.

Authors:  W D Leslie
Journal:  Osteoporos Int       Date:  2008-02-01       Impact factor: 4.507

Review 5.  A systematic review of interventions to improve recall of medical advice in healthcare consultations.

Authors:  Philip W B Watson; Brian McKinstry
Journal:  J R Soc Med       Date:  2009-06       Impact factor: 5.344

6.  Patient learning of treatment contents in cognitive therapy.

Authors:  Nicole B Gumport; Lu Dong; Jason Y Lee; Allison G Harvey
Journal:  J Behav Ther Exp Psychiatry       Date:  2017-08-31

7.  The development and validation of the Memory Support Rating Scale.

Authors:  Jason Y Lee; Frank C Worrell; Allison G Harvey
Journal:  Psychol Assess       Date:  2015-09-21

8.  Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world.

Authors:  H Ideguchi; S Ohno; H Hattori; Y Ishigatsubo
Journal:  Osteoporos Int       Date:  2007-06-19       Impact factor: 4.507

9.  Determinants of adherence to osteoporosis treatment in clinical practice.

Authors:  M Rossini; G Bianchi; O Di Munno; S Giannini; S Minisola; L Sinigaglia; S Adami
Journal:  Osteoporos Int       Date:  2006-03-15       Impact factor: 4.507

10.  Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.